Weil Brian R, Suzuki Gen, Leiker Merced M, Fallavollita James A, Canty John M
From the Departments of Medicine, Physiology and Biophysics and Biomedical Engineering, and the Clinical and Translational Research Center, University at Buffalo and the VA WNY Health Care System, NY.
Circ Res. 2015 Sep 11;117(7):634-44. doi: 10.1161/CIRCRESAHA.115.306850. Epub 2015 Aug 13.
Allogeneic bone marrow-derived mesenchymal stem cells (MSCs) and cardiosphere-derived cells (CDCs) have each entered clinical trials, but a direct comparison of these cell types has not been performed in a large animal model of hibernating myocardium.
Using completely blinded methodology, we compared the efficacy of global intracoronary allogeneic MSCs (icMSCs, ≈35×10(6)) and CDCs (icCDCs, ≈35×10(6)) versus vehicle in cyclosporine-immunosuppressed swine with a chronic left anterior descending coronary artery stenosis (n=26).
Studies began 3 months after instrumentation when wall thickening was reduced (left anterior descending coronary artery % wall thickening [mean±SD], 38±11% versus 83±26% in remote; P<0.01) and similar among groups. Four weeks after treatment, left anterior descending coronary artery % wall thickening increased similarly after icCDCs and icMSCs, whereas it remained depressed in vehicle-treated controls (icMSCs, 51±13%; icCDCs, 51±17%; vehicle, 34±3%, treatments P<0.05 versus vehicle). There was no change in myocardial perfusion. Both icMSCs and icCDCs increased left anterior descending coronary artery myocyte nuclear density (icMSCs, 1601±279 nuclei/mm(2); icCDCs, 1569±294 nuclei/mm(2); vehicle, 973±181 nuclei/mm(2); treatments P<0.05 versus vehicle) and reduced myocyte diameter (icMSCs, 16.4±1.5 μm; icCDCs, 16.8±1.2 μm; vehicle, 20.2±3.7 μm; treatments P<0.05 versus vehicle) to the same extent. Similar changes in myocyte nuclear density and diameter were observed in the remote region of cell-treated animals. Cell fate analysis using Y-chromosome fluorescent in situ hybridization demonstrated rare cells from sex-mismatched donors.
Allogeneic icMSCs and icCDCs exhibit comparable therapeutic efficacy in a large animal model of hibernating myocardium. Both cell types produced equivalent increases in regional function and stimulated myocyte regeneration in ischemic and remote myocardium. The activation of endogenous myocyte proliferation and regression of myocyte cellular hypertrophy support a common mechanism of cardiac repair.
异体骨髓间充质干细胞(MSCs)和心球衍生细胞(CDCs)均已进入临床试验,但尚未在冬眠心肌的大型动物模型中对这些细胞类型进行直接比较。
采用完全盲法,我们比较了环孢素免疫抑制的慢性左前降支冠状动脉狭窄猪(n = 26)中,冠状动脉内注射异体MSCs(icMSCs,约35×10⁶)和CDCs(icCDCs,约35×10⁶)与注射赋形剂的疗效。
在植入仪器3个月后,当室壁增厚减少时(左前降支冠状动脉壁增厚百分比[均值±标准差],38±11%,而远隔部位为83±26%;P<0.01)且各组间相似时开始研究。治疗4周后,icCDCs和icMSCs治疗后左前降支冠状动脉壁增厚百分比相似增加,而赋形剂治疗的对照组则持续降低(icMSCs,51±13%;icCDCs,51±17%;赋形剂,34±3%,治疗组与赋形剂组相比P<0.05)。心肌灌注无变化。icMSCs和icCDCs均增加了左前降支冠状动脉心肌细胞核密度(icMSCs,1601±279个细胞核/mm²;icCDCs,1569±294个细胞核/mm²;赋形剂,973±181个细胞核/mm²;治疗组与赋形剂组相比P<0.05),并同等程度地减小了心肌细胞直径(icMSCs,16.4±1.5μm;icCDCs,16.8±1.2μm;赋形剂,20.2±3.7μm;治疗组与赋形剂组相比P<0.05)。在细胞治疗动物的远隔区域观察到心肌细胞核密度和直径有类似变化。使用Y染色体荧光原位杂交进行的细胞命运分析显示,来自性别不匹配供体的细胞很少。
在冬眠心肌的大型动物模型中,异体icMSCs和icCDCs表现出相当的治疗效果。两种细胞类型在局部功能上均产生了同等程度的增加,并刺激了缺血心肌和远隔心肌中的心肌细胞再生。内源性心肌细胞增殖的激活和心肌细胞肥大的消退支持了心脏修复的共同机制。